Copertina

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jiamei Wang, Feng Wen, Jian Zhao
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
di: Jian Wang, et al.
Pubblicazione: (2024)

Prospective evaluation of patients with non‐cirrhotic portal hypertension: A single centre study
di: Maria Mironova, et al.
Pubblicazione: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
di: Hyeyeon Hong, et al.
Pubblicazione: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
di: Jian Wang, et al.
Pubblicazione: (2024)

Other causes of neurocognitive impairment than covert hepatic encephalopathy ( CHE ) are very frequent, either alone or associated with CHE , in cirrhotic patients with cognitive complaints
di: Philippe Sultanik, et al.
Pubblicazione: (2024)

Letter: Resmetirom for treatment of MASH with children and adolescents
di: Yong‐Hai Zhou, et al.
Pubblicazione: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply
di: WenXian OuYang, et al.
Pubblicazione: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
di: Jian Wang, et al.
Pubblicazione: (2024)

Letter: Geographic Transportability of Shingles Risk With Advanced IBD Therapies
di: Guofu Mao, et al.
Pubblicazione: (2026)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
di: Mingsi Zhang, et al.
Pubblicazione: (2024)

Letter: Addressing opioid exposure and associated harms in patients with IBD
di: Christian P. Selinger, et al.
Pubblicazione: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
di: Chen‐Pi Li, et al.
Pubblicazione: (2024)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
di: Zhidong Zhou, et al.
Pubblicazione: (2025)

Letter: Unmasking the Risks—The Need for Robust Data on Baclofen in Cirrhotic Patients
di: Zainab Salman
Pubblicazione: (2026)

Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors
di: Xueneng Yang, et al.
Pubblicazione: (2025)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
di: Jing Li, et al.
Pubblicazione: (2024)

Letter: Diet to Modify Risk of IBD—More Plants and Less Processed Food?
di: Alice S. Day, et al.
Pubblicazione: (2025)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
di: Elliot B. Tapper, et al.
Pubblicazione: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
di: Ivan Arcari, et al.
Pubblicazione: (2024)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
di: Zhejin Shi, et al.
Pubblicazione: (2026)

Letter: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
di: Jiaqi Shen, et al.
Pubblicazione: (2026)

Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport
di: Emmanuel Pio Pastore
Pubblicazione: (2025)

Letter: Enhancing Risk‐Adapted Colorectal Cancer Screening for People With Diabetes—Authors' Reply
di: Teresa Seum, et al.
Pubblicazione: (2025)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis
di: Fang Yan, et al.
Pubblicazione: (2024)

Letter: Refining the Understanding of Hepatic Steatosis and Cardiovascular Risk—Addressing Key Variables and Subgroup Analyses
di: Changhu Sun, et al.
Pubblicazione: (2025)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate
di: Wen‐Juei Jeng, et al.
Pubblicazione: (2025)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find
di: Leya Nedumannil, et al.
Pubblicazione: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
di: Stuart McPherson, et al.
Pubblicazione: (2024)

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease
di: Jannis Kountouras, et al.
Pubblicazione: (2024)

Letter: Boosting non‐invasive tests—Opportunities and challenges from resmetirom
di: Gong Feng, et al.
Pubblicazione: (2024)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Letter: H. pylori Infection May Constitute a Risk Factor for Reflux Disease and Colonic Neoplasia
di: Jannis Kountouras, et al.
Pubblicazione: (2025)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
di: David Bergman, et al.
Pubblicazione: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
di: Lukas Burghart, et al.
Pubblicazione: (2024)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
di: Jia‐Yong Su, et al.
Pubblicazione: (2025)

Long‐term clinical outcomes of extracorporeal shockwave lithotripsy and endoscopic retrograde cholangiopancreatography for pancreatic duct stone treatment in patients with chronic pancreatitis
di: Yu Liu, et al.
Pubblicazione: (2024)

Letter: Critical Insights on a Nationwide Cohort Study of Inflammatory Bowel Disease, Histological Activity and Fracture Risk
di: Saad Khan, et al.
Pubblicazione: (2024)

Letter on ‘Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis’
di: Yi Pei, et al.
Pubblicazione: (2025)

Letter: Interpreting Apparent P‐ CAB Superiority for Antithrombotic‐Associated Upper Gastrointestinal Bleeding
di: Xiaoqing Yang, et al.
Pubblicazione: (2026)